Other-Net, Expense (Income)

12 Months Ended

Dec. 31, 2011

Other-Net, Expense [Abstract]

Other - Net, Expense (Income) [Text Block]

Note 17: Other—Net, Expense:

Other—net, expense consisted of the following:

	2011	2010	2009
Interest expense	$186.0	$185.5	$261.3
Interest income	(79.9)	(51.9)	(75.2)
Other (income) expense	72.9	(128.6)	43.4
Other—net, expense	$179.0	$    5.0	$229.5

Other expense for the year ended December 31, 2011 primarily consists of the partial impairment on acquired IPR&D assets related to liprotamase and Amyvid (Note 7) partially offset by gains on the disposal of investment securities. For the year ended December 31, 2010, other (income) expense primarily consists of damages recovered from generic pharmaceutical companies related to Zyprexa patent litigation in Germany and gains on the disposal of investment securities.